8-bromocyclic-gmp and pimagedine

The pleiotropic cytokine interleukin-1 (IL-1) is an inducer of the inducible nitric oxide synthase (iNOS). It was surprising to find that treatment of normal mice with an iNOS inhibitor resulted in detectable IL-1beta mRNA in colon and spleen, suggesting feedback regulation. When mouse peritoneal exudate cells (PEC) or RAW 264.7 cells were stimulated with lipopolysaccharide (LPS), concomitant inhibition of iNOS resulted in an increase of IL-1beta and IL-1alpha protein secretion. Conversely, after addition of the NO-generating compound NOC-18, IL-1beta and IL-1alpha concentrations in supernatants were dose-dependently reduced. Costimulation with interferon-gamma (IFN-gamma) reversed the NOC-18-mediated suppression of IL-1alpha protein concentration into an almost fivefold increase in RAW 264.7 cells. This effect was specific for IL-1alpha and was also seen in PEC. The mRNA expression for IL-1beta and IL-1alpha in RAW 264.7 cells correlated with the protein levels, suggesting transcriptional regulation by NO. Dysregulated IL-1/NO cross-regulation may play a role in inflammatory diseases.

Topics: Animals; Cell Line; Cyclic GMP; Enzyme Inhibitors; Feedback; Female; Guanidines; Interferon-gamma; Interleukin-1; Macrophages; Male; Mice; Mice, Inbred BALB C; Nitric Oxide Synthase; Nitric Oxide Synthase Type II

High concentrations of nitric oxide (NO) inhibit bone resorption by mature osteoclasts. We examined the effects of low NO concentrations on osteoclast formation in mouse bone marrow cultures. The NO releasers sodium nitroprusside (SNP) and S-nitroso-N-acetyl-DL-penicillamine inhibited the formation of multinucleated cells expressing tartrate-resistant acid phosphatase (a marker for osteoclasts) when administered during the last 3 days of 6-day cultures (differentiation stage) but not during the first 3 days (proliferation stage). SNP (1 microM) completely inhibited pit formation on dentine wafers when added to cultures during osteoclast formation, but 100 microM SNP was required to inhibit pitting by mature osteoclasts. Conversely, the NO synthase inhibitors aminoguanidine and nitro-L-arginine methyl ester both increased osteoclast formation. Inhibition of osteoclast formation by NO likely was guanosine 3',5'-cyclic monophosphate (cGMP) dependent, as SNP increased cGMP in marrow cultures, and 1 mM 8-bromo-cGMP or dibutyryl-cGMP reduced osteoclast formation when administered during the differentiation stage. The cGMP-specific type V phosphodiesterase inhibitor, zaprinast (M & B 22948) also inhibited osteoclast formation (half-maximal inhibitory constant, 100 microM) only when added during the differentiation stage. We conclude that the differentiation stage of osteoclast formation is inhibited by increases in cGMP levels elicited by NO.

Topics: 8-Bromo Cyclic Adenosine Monophosphate; Animals; Bone Marrow Cells; Bone Resorption; Bucladesine; Calcitriol; Cells, Cultured; Cyclic GMP; Dentin; Dibutyryl Cyclic GMP; Guanidines; In Vitro Techniques; Mice; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Nitroprusside; Osteoclasts; Penicillamine; Purinones; S-Nitroso-N-Acetylpenicillamine; Whales